Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - engelsk - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 100 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 50 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Den europeiske union - fransk - EMA (European Medicines Agency)

astrazeneca ab - palivizumab - infections respiratoires du virus syncytial - des sérums et immunoglobulines, - synagis est indiqué pour la prévention de graves basse-respiratoire-maladies des voies nécessitant une hospitalisation causée par le virus respiratoire syncytial (vrs) chez les enfants à haut risque pour la maladie de la rsv:les enfants nés à 35 semaines de gestation ou de moins en moins de six mois d'âge au début de la saison de vrs.; enfants de moins de deux ans de l'âge et nécessitant un traitement de la dysplasie broncho-pulmonaire au cours des six derniers mois;les enfants de moins de deux ans de l'âge et présentant des répercussions hémodynamiques maladie cardiaque congénitale importante.

Israel - hebraisk - Ministry of Health

agis commercial agency (1989) - ciclesonide 40 mcg - solution for inhalation - ciclesonide - treatment to control persistent asthma in adults and adolescents ( 12 years and older) .